TScan Therapeutics, Inc. (TCRX) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
TCRX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
TCRX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 72.2% | -1315.4% | -1256.8% |
| 2024 | 100.0% | -4787.7% | -4527.7% |
| 2023 | 100.0% | -444.0% | -423.9% |
| 2022 | 100.0% | -492.3% | -489.3% |
| 2021 | 100.0% | -479.6% | -479.5% |
Download Data
Export TCRX earnings history in CSV or JSON format
Free sign-in required to download data
TScan Therapeutics, Inc. (TCRX) Earnings Overview
As of May 8, 2026, TScan Therapeutics, Inc. (TCRX) reported trailing twelve-month net income of -$124M, reflecting +12.3% year-over-year growth. The company earned $-0.96 per diluted share over the past four quarters, with a net profit margin of -1256.8%.
Looking at the long-term picture, TCRX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$14M in fiscal 2019.
TScan Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including IMVT (-$464M net income), TCRT (-$4M net income, -46790.0% margin), AGEN ($115,000 net income, 0.1% margin), TCRX has comparable earnings metrics. Compare TCRX vs IMVT →
TCRX Earnings vs Peers
Earnings metrics vs comparable public companies
TCRX Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$130M | -1.8% | -$136M | $-1.00 | -1256.8% | -1315.4% |
| 2024 | -$127M | -42.9% | -$135M | $-1.14 | -4527.7% | -4787.7% |
| 2023 | -$89M | -34.7% | -$93M | $-1.36 | -423.9% | -444.0% |
| 2022 | -$66M | -36.2% | -$67M | $-2.74 | -489.3% | -492.3% |
| 2021 | -$49M | -86.1% | -$49M | $-2.03 | -479.5% | -479.6% |
| 2020 | -$26M | -91.3% | -$26M | $-1.04 | -2408.0% | -2417.8% |
| 2019 | -$14M | - | -$14M | $-0.53 | - | - |
See TCRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TCRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TCRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTCRX — Frequently Asked Questions
Quick answers to the most common questions about buying TCRX stock.
Is TCRX growing earnings?
TCRX EPS stands at $-0.96, with +12.3% growth matching the 5-year CAGR of N/A. TTM net income is $-124M. Earnings trajectory remains consistent.
What are TCRX's profit margins?
TScan Therapeutics, Inc. net margin is -1256.8%, with operating margin at -1315.4%. Below-average margins reflect competitive or cost pressures.
How consistent are TCRX's earnings?
TCRX earnings data spans 2019-2025. The current earnings trend is +12.3% YoY. Historical data enables comparison across business cycles.